October 12th 2024, 6:00pm
The drug combined with chemotherapy demonstrated a 60% increase in progression-free survival, suggesting signs of an FDA approval.
October 7th 2024, 9:00pm
For patients with metastatic colorectal cancer, adding a higher dose proves just as effective as the standard dose of vitamin D3, despite one exception.
September 21st 2024, 2:00pm
At the 2024 ESMO Congress, CURE® spoke with an expert about Fotivda and certain challenges patients may experience, such as side effects.
September 20th 2024, 12:59pm
The discussion will wrap up with perspectives on the future of CLL treatment, including anticipated improvements in patient care and quality of life, emerging therapies, and evolving patient roles in care decisions.
September 20th 2024, 12:57pm
The discussion will explore the impact of fixed-duration treatments on quality of life, benefits and challenges compared with continuous therapy, financial considerations, and lifestyle goals during and after treatment.
September 16th 2024, 3:00pm
At the 2024 ESMO Congress, an expert explained how Nubeqa may reduce fatigue-related side effects in metastatic hormone-sensitive prostate cancer.
September 13th 2024, 2:54pm
The discussion will cover fixed-duration treatments vs continuous therapy for CLL and provide a brief overview of venetoclax-based regimens approved for 12 cycles with obinutuzumab and 24 cycles with rituximab.
September 13th 2024, 2:52pm
The discussion will cover experiences with CLL treatment, focusing on key factors in treatment decisions, how care teams educate patients about options, strategies for discussing adverse events, and communicating adverse effects to the care team.
September 9th 2024, 3:00pm
Spleen size, blood counts and symptom burden are some of the factors cancer teams take into account when selecting which of the four JAK inhibitors to treat patient with myelofibrosis.
September 6th 2024, 2:50pm
The discussion will cover the current CLL treatment landscape, including first-line and later-line options; the medical experts will review first-line treatments, approach to treatment selection, factors influencing recommendations, and strategies for shared decision-making with patients.
FDA OKs Imfinzi for Limited-Stage Small Cell Lung Cancer
FDA Approves Bizengri for Some with NSCLC, Pancreatic Adenocarcinoma
Expert Explains Lymphoma After Dave Coulier's Diagnosis
Time, My Most Precious Gift After Breast Cancer